OBJECTIVE: To evaluate the effect of hormone replacement therapy on climacteric ocular complaints, lacrimal secretion, intraocular pressure (IOP), and corneal thickness. DESIGN: A prospective, controlled, randomized study on 50 healthy women (mean age 53.4 +/- 3.8 years) at least 1 year after spontaneous menopause. Twenty-five women (group A) were treated with transdermal 17beta-estradiol (50 microg/day) and medroxyprogesterone acetate (10 mg/day) for 12 days per cycle. Twenty-five untreated women (group B) were used as a control group. All participants underwent eye examination at the beginning of the study and after 3 and 6 months of therapy to detect ocular diseases and to measure lachrymal secretion, IOP, and corneal thickness. RESULTS: No significant differences were observed between the two groups at the beginning of the study. After 3 and 6 months of treatment, we observed a significant reduction in the percentage of women in group A affected by ocular symptoms and in the severity of symptomatology in comparison with baseline and with group B (P < 0.01). A significant increase of both basal and stimulated lachrymal secretion was observed after 3 months of therapy in group A in comparison with baseline (P < 0.01). There was a significant decrease of IOP (P < 0.01) after 3 months of therapy in group A (P < 0.01), and a slight, nonsignificant increase of corneal thickness was observed in group A at 3 and 6 months in comparison with basal values. CONCLUSION: Our data suggest that hormone replacement therapy may exert a beneficial effect on ocular symptomatology, increase lachrymal secretion, reduce IOP, and increase corneal thickness.
RCT Entities:
OBJECTIVE: To evaluate the effect of hormone replacement therapy on climacteric ocular complaints, lacrimal secretion, intraocular pressure (IOP), and corneal thickness. DESIGN: A prospective, controlled, randomized study on 50 healthy women (mean age 53.4 +/- 3.8 years) at least 1 year after spontaneous menopause. Twenty-five women (group A) were treated with transdermal 17beta-estradiol (50 microg/day) and medroxyprogesterone acetate (10 mg/day) for 12 days per cycle. Twenty-five untreated women (group B) were used as a control group. All participants underwent eye examination at the beginning of the study and after 3 and 6 months of therapy to detect ocular diseases and to measure lachrymal secretion, IOP, and corneal thickness. RESULTS: No significant differences were observed between the two groups at the beginning of the study. After 3 and 6 months of treatment, we observed a significant reduction in the percentage of women in group A affected by ocular symptoms and in the severity of symptomatology in comparison with baseline and with group B (P < 0.01). A significant increase of both basal and stimulated lachrymal secretion was observed after 3 months of therapy in group A in comparison with baseline (P < 0.01). There was a significant decrease of IOP (P < 0.01) after 3 months of therapy in group A (P < 0.01), and a slight, nonsignificant increase of corneal thickness was observed in group A at 3 and 6 months in comparison with basal values. CONCLUSION: Our data suggest that hormone replacement therapy may exert a beneficial effect on ocular symptomatology, increase lachrymal secretion, reduce IOP, and increase corneal thickness.
Authors: Janey L Wiggs; Jae Hee Kang; Brian L Yaspan; Daniel B Mirel; Cathy Laurie; Andrew Crenshaw; Wendy Brodeur; Stephanie Gogarten; Lana M Olson; Wael Abdrabou; Elizabeth DelBono; Stephanie Loomis; Jonathan L Haines; Louis R Pasquale Journal: Hum Mol Genet Date: 2011-08-26 Impact factor: 6.150
Authors: Paula Anne Newman-Casey; Nidhi Talwar; Bin Nan; David C Musch; Louis R Pasquale; Joshua D Stein Journal: JAMA Ophthalmol Date: 2014-03 Impact factor: 7.389
Authors: Raheleh Rahimi Darabad; Tomo Suzuki; Stephen M Richards; Frederick A Jakobiec; Fouad R Zakka; Stefano Barabino; David A Sullivan Journal: Exp Eye Res Date: 2014-07-30 Impact factor: 3.467
Authors: Jae Hee Kang; Janey L Wiggs; Bernard A Rosner; Susan E Hankinson; Wael Abdrabou; Bao Jian Fan; Jonathan Haines; Louis R Pasquale Journal: Invest Ophthalmol Vis Sci Date: 2009-10-08 Impact factor: 4.799